FCF $656m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+11.0%TTM YoYB
Revenue +11.0% — at or above S&P median
D/E0.17A
D/E 0.17 — least levered decile in Energy (≈10th pctile)
P/E157.7xD
P/E 157.7 — most expensive decile in Energy (≈95th pctile)
PEG1.92C+
PEG 1.92 — modest premium; above fair value
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 45.6
Quality0.66
Growth0.50
Value0.33
Why this score
Cyclical growth
Foreign reporter (CAD)
Entry · Margin of safety
52-week rangeMid-range
30% off the 12-month high
vs DCF fair value166% aboveest. fair value ~$36
What the price assumes: free cash flow compounding at ~41% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability9% · Cgross profit ÷ total assets (Novy-Marx)
ROIC6.2% · C+return on invested capital — not score-weighted
Why now
Uranium · market cap $41.2b. Down 30% from 52-week high of $135.24 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $133.25 (implying +41% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trailing P/E 157.7x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 30% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. P/S 16.7x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon
1-3 yr $133.25 (11-analyst consensus) — fundamentals + valuation re-rating. 5 yr $195.09 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $289.41 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
CCJ vs the Top Picks average
Pillar
CCJ
Book avg
Diff
Quality
0.66
0.83
-0.16
Growth
0.50
0.91
-0.41
Value
0.33
0.75
-0.41
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · CCJ
Trend
-3.2 over 32 daily scores
From 48.8 (Jun 22) → 45.6 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · CCJ
$
%
%
Shares to buy
21
Position size
$1,987
4.0% of portfolio
Stop price
$70.96
25% below $94.61
$ at risk if stopped
$496.70
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Cameco Corporation (CCJ): score, valuation & FAQ
Cameco Corporation (CCJ) is a Uranium company that scores 45.6 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A), while P/E (D) rate weaker. On valuation, CCJ sits about 166% above our discounted-cash-flow fair value — the current price implies roughly 41% annual free-cash-flow growth over the next decade.
Is CCJ a good stock to buy?
Bull Rankings scores CCJ 45.6 out of 100 on its quality-growth model, which is a below-average reading. That is driven by D/E (A). A score is a quantitative screen of Cameco Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CCJ score 45.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CCJ earns its highest marks on D/E (A), and is held back by P/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CCJ overvalued or undervalued?
Based on $94.61, CCJ sits about 166% above our discounted-cash-flow fair value — the current price implies roughly 41% annual free-cash-flow growth over the next decade. It trades at a 157.7x× P/E (graded D). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CCJ?
Trailing P/E 157.7x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 30% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. P/S 16.7x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.